MCMaxime Caron

Maxime Caron

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Maxime Caron has a total of 318 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    EpiATLAS - a reference for human epigenomic research

    by Quirin Manz, Misha Bilenky, Dennis Hecker, Nihit Aggarwal, Juliana E Arcila-Galvis, Shamim Ashrafiyan, Nina Baumgarten, Fatemeh Behjati Ardakani, Paulo R Branco Lins, Charles E Breeze, et al.

    The sequence of the human genome provides a foundation for understanding cellular processes in health and disease. The organisation of this primary genetic information into cell-specific structure and function is critical to understanding the cell type-specific interpretation and execution of the genome. Epigenetic processes are essential for packaging and higher-level functional organisation of the genome, and changes therein are increasingly recognised as contributors to human disease. Building on primary data generated by multinational consortia, the International Human Epigenome Consortium (IHEC) has uniformly processed a collection of more than 2000 comprehensive human reference epigenomes, collectively referred to as EpiATLAS. This effort involved the development of standardised molecular and bioinformatics protocols, metadata models, and analytical tools to manage, integrate, display, and share vast amounts of epigenomic data. This includes the creation of a publicly available Epigenome Reference Registry, which provides a system for accessing protected human subject datasets and facilitates open searching of de-identified samples and experimental data. The integrated EpiATLAS ecosystem and its comprehensive human reference epigenome maps provide an unprecedented resource for the biosciences, expanding the annotated epigenomic landscape while uncovering previously unappreciated relationships among regulatory layers and revealing how epigenetic inputs underpin fundamental cellular functions and disease associations.


  • Open Access

    Mannose Receptor C type 2 influences autoimmune neuroinflammation and blood-brain barrier integrity

    by Bettina Zierfuss, Melanie Käch, Camille Sugère, Marion Morvan, Haritha Desu, Sandra Larouche, Skander Ben Ahmed, Wendy Klement, Karine Thai, Camille Grasmuck, et al.

    Relapses in Multiple Sclerosis (MS) are driven by pathogenic immune cells breaching the disrupted blood–brain barrier (BBB), leading to tissue damage and eventual disease progression1–3. Among the most effective therapies are those that block immune cell infiltration across the BBB, a multistep process involving activation, adhesion, rolling, transendothelial migration, and extracellular matrix (ECM) degradation. Current treatments broadly suppress the immune system and can cause adverse side effects4,5, highlighting the need for targeted approaches. Here, we identified a previously unrecognized role of ECM remodeling pathways and Mannose Receptor C-type 2 (MRC2) in invasive T lymphocytes as a potential therapeutic target. Typically low under physiological conditions, MRC2 was upregulated on T lymphocytes upon inflammatory stimulation in vitro, enriched in the periphery of MS patients during relapse and progressive disease, and present in cerebrospinal fluid and active brain lesions co-localized with Col IV, the major ECM component of the BBB. Genetic deletion of MRC2 impaired T lymphocyte-mediated Col IV degradation, adhesion, and transendothelial migration, and leading to reduced neuroinflammation in a sex-dependent manner in an MS-like mouse model. These findings suggest MRC2 as a key regulator of T lymphocyte infiltration into the CNS and a promising target for MS therapy.


  • Open Access

    Rescuing DNMT1 fails to fully reverse the molecular and functional repercussions of its loss in mouse embryonic stem cells

    by Elizabeth Elder, Anthony Lemieux, Lisa-Marie Legault, Maxime Caron, Virginie Bertrand-Lehouillier, Thomas Dupas, Noël J-M Raynal, Guillaume Bourque, Daniel Sinnett, Nicolas Gévry, et al.

    Epigenetic mechanisms are crucial for developmental programming and can be disrupted by environmental stressors, increasing susceptibility to disease. This has sparked interest in therapies for restoring epigenetic balance, but it remains uncertain whether disordered epigenetic mechanisms can be fully corrected. Disruption of DNA methyltransferase 1 (DNMT1), responsible for DNA methylation maintenance, has particularly devastating biological consequences. Therefore, here we explored if rescuing DNMT1 activity is sufficient to reverse the effects of its loss utilizing mouse embryonic stem cells. However, only partial reversal could be achieved. Extensive changes in DNA methylation, histone modifications, and gene expression were detected, along with transposable element derepression and genomic instability. Reduction of cellular size, complexity, and proliferation rate were observed, as well as lasting effects in germ layer lineages and embryoid bodies. Interestingly, by analyzing the impact on imprinted regions, we uncovered 20 regions exhibiting imprinted-like signatures. Notably, while many permanent effects persisted throughout Dnmt1 inactivation and rescue, others arose from the rescue intervention. Lastly, rescuing DNMT1 after differentiation initiation worsened outcomes, reinforcing the need for early intervention. Our findings highlight the far-reaching functions of DNMT1 and provide valuable perspectives on the repercussions of epigenetic perturbations during early development and the challenges of rescue interventions.


  • Open Access

    CircRNAome of Childhood Acute Lymphoblastic Leukemia: Deciphering Subtype-Specific Expression Profiles and Involvement in TCF3::PBX1 ALL

    by Angela Gutierrez-Camino, Maxime Caron, Chantal Richer, Claire Fuchs, Unai Illarregi, Lucas Poncelet, Pascal St-Onge, Alain R. Bataille, Pascal Tremblay-Dauphinais, Elixabet Lopez-Lopez, et al.

    Childhood B-cell acute lymphoblastic leukemia (B-ALL) is a heterogeneous disease comprising multiple molecular subgroups with subtype-specific expression profiles. Recently, a new type of ncRNA, termed circular RNA (circRNA), has emerged as a promising biomarker in cancer, but little is known about their role in childhood B-ALL. Here, through RNA-seq analysis in 105 childhood B-ALL patients comprising six genetic subtypes and seven B-cell controls from two independent cohorts we demonstrated that circRNAs properly stratified B-ALL subtypes. By differential expression analysis of each subtype vs. controls, 156 overexpressed and 134 underexpressed circRNAs were identified consistently in at least one subtype, most of them with subtype-specific expression. TCF3::PBX1 subtype was the one with the highest number of unique and overexpressed circRNAs, and the circRNA signature could effectively discriminate new patients with TCF3::PBX1 subtype from others. Our results indicated that NUDT21, an RNA-binding protein (RBP) involved in circRNA biogenesis, may contribute to this circRNA enrichment in TCF3::PBX1 ALL. Further functional characterization using the CRISPR-Cas13d system demonstrated that circBARD1, overexpressed in TCF3::PBX1 patients and regulated by NUDT21, might be involved in leukemogenesis through the activation of p38 via hsa-miR-153-5p. Our results suggest that circRNAs could play a role in the pathogenesis of childhood B-ALL.


  • Open Access

    Characterisation of FLT3 alterations in childhood acute lymphoblastic leukaemia

    by Angela Gutierrez-Camino, Chantal Richer, Manon Ouimet, Claire Fuchs, Sylvie Langlois, Fida Khater, Maxime Caron, Patrick Beaulieu, Pascal St-Onge, Alain R. Bataille, et al.

    Background: Alterations of FLT3 are among the most common driver events in acute leukaemia with important clinical implications, since it allows patient classification into prognostic groups and the possibility of personalising therapy thanks to the availability of FLT3 inhibitors. Most of the knowledge on FLT3 implications comes from the study of acute myeloid leukaemia and so far, few studies have been performed in other leukaemias. Methods: A comprehensive genomic (DNA-seq in 267 patients) and transcriptomic (RNA-seq in 160 patients) analysis of FLT3 in 342 childhood acute lymphoblastic leukaemia (ALL) patients was performed. Mutations were functionally characterised by in vitro experiments. Results: Point mutations (PM) and internal tandem duplications (ITD) were detected in 4.3% and 2.7% of the patients, respectively. A new activating mutation of the TKD, G846D, conferred oncogenic properties and sorafenib resistance. Moreover, a novel alteration involving the circularisation of read-through transcripts (rt-circRNAs) was observed in 10% of the cases. Patients presenting FLT3 alterations exhibited higher levels of the receptor. In addition, patients with ZNF384- and MLL/KMT2A-rearranged ALL, as well as hyperdiploid subtype, overexpressed FLT3. Discussion: Our results suggest that specific ALL subgroups may also benefit from a deeper understanding of the biology of FLT3 alterations and their clinical implications.


  • Open Access

    Diverse mutations and structural variations contribute to Notch signaling deregulation in paediatric T‐cell lymphoblastic lymphoma

    by Julia Salmerón‐Villalobos, Joan Enric Ramis‐Zaldivar, Olga Balagué, Jaime Verdú‐Amorós, Verónica Celis, Constantino Sábado, Marta Garrido, Sara Mato, Javier Uriz, M. José Ortega, et al.

    Background: T‐cell lymphoblastic lymphoma (T‐LBL) is an aggressive neoplasm closely related to T‐cell acute lymphoblastic leukaemia (T‐ALL). Despite their similarities, and contrary to T‐ALL, studies on paediatric T‐LBL are scarce and, therefore, its molecular landscape has not yet been fully elucidated. Thus, the aims of this study were to characterize the genetic and molecular heterogeneity of paediatric T‐LBL and to evaluate novel molecular markers differentiating this entity from T‐ALL.Procedure: Thirty‐three paediatric T‐LBL patients were analyzed using an integrated approach, including targeted next‐generation sequencing, RNA‐sequencing transcriptome analysis and copy‐number arrays.Results: Copy number and mutational analyses allowed the detection of recurrent homozygous deletions of 9p/CDKN2A (78%), trisomy 20 (19%) and gains of 17q24‐q25 (16%), as well as frequent mutations of NOTCH1 (62%), followed by the BCL11B (23%), WT1 (19%) and FBXW7, PHF6 and RPL10 genes (15%, respectively). This genetic profile did not differ from that described in T‐ALL in terms of mutation incidence and global genomic complexity level, but unveiled virtually exclusive 17q25 gains and trisomy 20 in T‐LBL. Additionally, we identified novel gene fusions in paediatric T‐LBL, including NOTCH1–IKZF2, RNGTT–SNAP91 and DDX3X–MLLT10, the last being the only one previously described in T‐ALL. Moreover, clinical correlations highlighted the presence of Notch pathway alterations as a factor related to favourable outcome.Conclusions: In summary, the genomic landscape of paediatric T‐LBL is similar to that observed in T‐ALL, and Notch signaling pathway deregulation remains the cornerstone in its pathogenesis, including not only mutations but fusion genes targeting NOTCH1.


  • Open Access

    Abstract 3897: Ribosomal translational regulation is a potential mechanism for leukemia-related thrombo-embolic event in childhood acute lymphoblastic leukemia

    by Marie-Claude Pelland-Marcotte, Meredith Michelle Rémy, Yan Ma, Jessica Liu, Camille Jimenez-Cortes, Thomas Sontag, Maxime Caron, Pascal Saint-Onge, Sylvie Langlois, Charles Joly-Beauparlant, et al.

    Introduction: Thrombo-embolic event (TE) is a frequent complication of childhood acute lymphoblastic leukemia (cALL) and is associated with reduced survival. Overexpression of podoplanin or coagulome genes and coagulation pathway activation have been identified in cancer-induced TE but the role of leukemia environment in TE occurrence has not been fully elucidated in ALL. We assessed whether leukemia gene expression (GE) signature at diagnosis was associated with TE development in cALL. Methods: We included children aged 0-18 years old (y.o.), from two hospitals, with newly diagnosed ALL and available RNA sequencing data from bone marrow at diagnosis. The primary outcome was the occurrence of grade ≥2 TE during ALL therapy using the Ponte Di Legno Working Group classification. TEs were classified as early (ET) if they occurred within 6 weeks from treatment start, or late (LT) otherwise. We compared differential gene expression (DE) in children with and without TE, adjusted for age (Citation Format: Marie-Claude Pelland-Marcotte, Meredith Michelle Rémy, Yan Ma, Jessica Liu, Camille Jimenez-Cortes, Thomas Sontag, Maxime Caron, Pascal Saint-Onge, Sylvie Langlois, Charles Joly-Beauparlant, Daniel Sinnett, Arnaud Droit, Thai Hoa Tran, Raoul Santiago. Ribosomal translational regulation is a potential mechanism for leukemia-related thrombo-embolic event in childhood acute lymphoblastic leukemia [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 3897.

  • Open Access

    Invasive growth associated with cold-inducible RNA-binding protein expression drives recurrence of surgically resected brain metastases

    by Matthew Dankner, Maxime Caron, Tariq Al-Saadi, WenQing Yu, Véronique Ouellet, Rima Ezzeddine, Sarah M Maritan, Matthew G Annis, Phuong Uyen Le, Javad Nadaf, et al.

    Background: Sixty percent of surgically resected brain metastases (BrM) recur within 1 year. These recurrences have long been thought to result from the dispersion of cancer cells during surgery. We tested the alternative hypothesis that invasion of cancer cells into the adjacent brain plays a significant role in local recurrence and shortened overall survival. Methods: We determined the invasion pattern of 164 surgically resected BrM and correlated with local recurrence and overall survival. We performed single-cell RNA sequencing (scRNAseq) of >15,000 cells from BrM and adjacent brain tissue. Validation of targets was performed with a novel cohort of BrM patient-derived xenografts (PDX) and patient tissues. Results: We demonstrate that invasion of metastatic cancer cells into the adjacent brain is associated with local recurrence and shortened overall survival. scRNAseq of paired tumor and adjacent brain samples confirmed the existence of invasive cancer cells in the tumor-adjacent brain. Analysis of these cells identified cold-inducible RNA-binding protein (CIRBP) overexpression in invasive cancer cells compared to cancer cells located within the metastases. Applying PDX models that recapitulate the invasion pattern observed in patients, we show that CIRBP is overexpressed in highly invasive BrM and is required for efficient invasive growth in the brain. Conclusions: These data demonstrate peritumoral invasion as a driver of treatment failure in BrM that is functionally mediated by CIRBP. These findings improve our understanding of the biology underlying postoperative treatment failure and lay the groundwork for rational clinical trial development based upon invasion pattern in surgically resected BrM.


  • Developmental genome-wide DNA methylation asymmetry between mouse placenta and embryo

    by Lm Legault, K Doiron, A Lemieux, M Caron, D Chan, Fl Lopes, G Bourque, D Sinnett, S McGraw

    In early embryos, DNA methylation is remodelled to initiate the developmental program but for mostly unknown reasons, methylation marks are acquired unequally between embryonic and placental cells. To better understand this, we generated high-resolution DNA methylation maps of mouse mid-gestation (E10.5) embryo and placenta. We uncovered specific subtypes of differentially methylated regions (DMRs) that contribute directly to the developmental asymmetry existing between mid-gestation embryonic and placental DNA methylation patterns. We show that the asymmetry occurs rapidly during the acquisition of marks in the post-implanted conceptus (E3.5-E6.5), and that these patterns are long-lasting across subtypes of DMRs throughout prenatal development and in somatic tissues. We reveal that at the peri–implantation stages, the de novo methyltransferase activity of DNMT3B is the main driver of methylation marks on asymmetric DMRs, and that DNMT3B can largely compensate for lack of DNMT3A in the epiblast and extraembryonic ectoderm, whereas DNMT3A can only partially compensate in the absence of DNMT3B. However, as development progresses and as DNMT3A becomes the principal de novo methyltransferase, the compensatory DNA methylation mechanism of DNMT3B on DMRs becomes less effective.


  • Open Access

    GenPipes: an open-source framework for distributed and scalable genomic analyses

    by Mathieu Bourgey, Rola Dali, Robert Eveleigh, Kuang Chung Chen, Louis Letourneau, Joel Fillon, Marc Michaud, Maxime Caron, Johanna Sandoval, Francois Lefebvre, et al.

    With the decreasing cost of sequencing and the rapid developments in genomics technologies and protocols, the need for validated bioinformatics software that enables efficient large-scale data processing is growing. Here we present GenPipes, a flexible Python-based framework that facilitates the development and deployment of multi-step workflows optimized for High Performance Computing clusters and the cloud. GenPipes already implements 12 validated and scalable pipelines for various genomics applications, including RNA-Seq, ChIP-Seq, DNA-Seq, Methyl-Seq, Hi-C, capture Hi-C, metagenomics and PacBio long read assembly. The software is available under a GPLv3 open source license and is continuously updated to follow recent advances in genomics and bioinformatics. The framework has been already configured on several servers and a docker image is also available to facilitate additional installations. In summary, GenPipes offers genomic researchers a simple method to analyze different types of data, customizable to their needs and resources, as well as the flexibility to create their own workflows.